中國中藥(0570.HK)高開9.43% 控股子公司受委託生產透解祛瘟顆粒
格隆匯2月10日丨中國中藥(0570.HK)跳空高開9.43%報4.64港元,盤前成交1606萬港元,最新總市值234億港元。公司今早公佈,根據廣東省藥品監督管理局發佈信息,廣州市第八人民醫院的醫院中藥製劑透解祛瘟顆粒通過廣東省醫療機構傳統中藥製劑應急審批備案,並委託公司控股子公司廣東一方製藥有限公司(廣東一方)進行生產配製。經廣東省疫情防控指揮部組織召開專家諮詢會,對透解祛瘟顆粒的臨牀觀察結果進行評估後認為:透解祛瘟顆粒能夠明顯改善新型冠狀病毒感染肺炎(輕症)的臨牀症狀,有減少重型肺炎發生的趨勢,具有較好的臨牀價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.